Clinical trial • Phase III • Infectious Disease
Cefiderocol for End-stage renal disease (patients on peritoneal dialysis)
Phase III trial of Cefiderocol for End-stage renal disease (patients on peritoneal dialysis). 6 participants.
Overview
- Trial Therapeutic Area
- Infectious Disease
- Trial Disease
- End-stage renal disease (patients on peritoneal dialysis)
- Trial Stage
- Phase III
- Drug Modality
- Small molecule
Key dates
- Initial CTIS Submission Date
- 27-01-2025
- First CTIS Authorization Date
- 14-05-2025
Trial design
Phase III trial across 1 site in Austria.
- Target Sample Size
- 6
Recruitment
- Planned Sample Size
- 6
- Recruitment Window Months
- 24
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 6
Austria
- Earliest CTIS Part Ii Submission Date
- 28-04-2025
- Latest Decision Or Authorization Date
- 14-05-2025
- Processing Time Days
- 16
- Number Of Sites
- 1
- Number Of Participants
- 6
Sites
- Site Name
- Medical University Of Vienna
- Department Name
- Department of Clinical Pharmacology
- Contact Person Name
- Markus Zeitlinger
- Contact Person Email
- markus.zeitlinger@meduniwien.ac.at
Sponsor
Primary sponsor
- Full Name
- Medical University Of Vienna
- Organisation Type
- Educational Institution
- Country Of Registered Address
- Austria
Investigational products
- Investigational Product Name
- Cefiderocol
- Active Substance
- Cefiderocol
- Modality
- Small molecule
Related trials
Other published trials that may interest you.
- Conditioned medium from a co-culture of M2-macrophages and fat-derived mesenchymal cells for Acute respiratory distress syndrome (ARDS) | SARS-CoV-2 infection | Influenza A infection | Influenza B infection | Respiratory syncytial virus (RSV) infection
- ACICLOVIR for Recurrent herpes labialis | Herpes simplex labialis
- AMIKACIN SULFATE for Sepsis | Neutropenia
- LENACAPAVIR, ISLATRAVIR for HIV-1 infection
- piperacillin sodium, tazobactam sodium for Extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae severe infection